Robert Wicke is an Operating Partner at BroadOak and helps lead the technical due diligence of the firm’s capital investing activities. Mr. Wicke has more than 30 years in Life Science leadership roles and hardware and software product development.  

Prior to BroadOak, he was CEO of Omniome, a NGS company which sold to PacBio for over $800 million. He also served as CEO of Halo Labs, a portfolio company of BroadOak’s. Robert was Senior Vice President of Global Instrumentation R&D at Pall Corporation, and General Manager of ForteBio, which sold to Sartorius for $750 million. Robert was Vice President of Product Development and Operations at ForteBio, which sold to Pall for 8x revenue. He served as Vice President of Product Development at Molecular Devices, which sold to MDS, and was Vice President of Engineering at Axon Instruments, Inc.  

Robert is on the Board of lino Biotech AG, and IXRF Systems, Inc. 

He earned his MSc of Computer Science from University of Oregon. He received his BSc in Computer Science and BSc in Mathematics from Drew University.  

When Robert isn’t helping Life Science companies reach their potential, he is a part-time professor of Computer Science and a substitute Math teacher for K-12. He is also an aspiring actor. Robert played Hamlet and Macbeth while studying Shakespeare at Oxford and hopes to one day get back on the stage. Until he does, Robert loves to spend time with his wife and two boys. He gardens with his youngest and rides bikes with his oldest. Robert lives in La Jolla, California, but is originally from New Jersey, and hence, cannot surf.